The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum

被引:6
|
作者
Chotivanich, Kesinee [1 ]
Mungthin, Mathirut [2 ]
Ruengweerayuth, Ronnatrai [3 ]
Udomsangpetch, Rachanee [4 ]
Dondorp, Arjen M. [1 ]
Singhasivanon, Pratap [1 ]
Pukrittayakamee, Sasithon [1 ]
White, Nicholas J. [1 ,5 ]
机构
[1] Mahidol Univ, Fac Trop Med, MORU, Bangkok 10400, Thailand
[2] Phramongkutklao Coll Med, Dept Parasitol, Bangkok 10400, Thailand
[3] Mae Sot Hosp, Tak, Thailand
[4] Mahidol Univ, Fac Sci, Dept Pathobiol, Bangkok 10400, Thailand
[5] Univ Oxford, Churchill Hosp, Ctr Trop Med, Oxford, England
来源
MALARIA JOURNAL | 2012年 / 11卷
基金
英国惠康基金;
关键词
Malaria; Anti-malarial drugs; In vitro-susceptibility; ANTIMALARIAL-DRUG RESISTANCE; ARTESUNATE-MEFLOQUINE; VIVAX MALARIA; CHLOROQUINE; BENFLUMETOL; BIOAVAILABILITY; HALOFANTRINE;
D O I
10.1186/1475-2875-11-177
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Lumefantrine and atovaquone are highly lipophilic anti-malarial drugs. As a consequence absorption is increased when the drugs are taken together with a fatty meal, but the free fraction of active drug decreases in the presence of triglyceride-rich plasma lipoproteins. In this study, the consequences of lipidaemia on anti-malarial drug efficacy were assessed in vitro. Methods: Serum was obtained from non-immune volunteers under fasting conditions and after ingestion of a high fat meal and used in standard Plasmodium falciparum in-vitro susceptibility assays. Anti-malarial drugs, including lumefantrine, atovaquone and chloroquine in five-fold dilutions (range 0.05 ng/ml - 1 ug/mL) were diluted in culture medium supplemented with fasting or post-prandial 10% donor serum. The in-vitro drug susceptibility of parasite isolates was determined using the H-3-hypoxanthine uptake inhibition method and expressed as the concentration which gave 50% inhibition of hypoxanthine uptake (IC50). Results: Doubling plasma triglyceride concentrations (from 160 mg/dL to 320 mg/dL), resulted in an approximate doubling of the IC50 for lumefantrine (191 ng/mL to 465 ng/mL, P < 0.01) and a 20-fold increase in the IC50 for atovaquone (0.5 ng/mL to 12 ng/ml; P < 0.01). In contrast, susceptibility to the hydrophilic anti-malarial chloroquine did not change in relation to triglyceride content of the medium. Conclusions: Lipidaemia reduces the anti-malarial activity of lipophilic anti-malarial drugs. This is an important confounder in laboratory in vitro testing and it could have therapeutic relevance.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] In vitro activity of quinolines against Plasmodium falciparum in Gabon
    Ramharter, M
    Wernsdorfer, WH
    Kremsner, PG
    ACTA TROPICA, 2004, 90 (01) : 55 - 60
  • [22] In vitro antimalarial activity of metalloporphyrins against Plasmodium falciparum
    Begum, K
    Kim, HS
    Kumar, V
    Stojiljkovic, I
    Wataya, Y
    PARASITOLOGY RESEARCH, 2003, 90 (03) : 221 - 224
  • [23] Synergistic interaction between atovaquone and retinol in Plasmodium falciparum in vitro
    Exner, Bettina
    Wernsdorfer, Gunther
    Sirichaisinthop, Jeeraphat
    Rojanawatsirivet, Chaiporn
    Kollaritsch, Herwig
    Wernsdorfer, Walther H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 : 45 - 52
  • [24] INTERACTIONS OF ATOVAQUONE WITH OTHER ANTIMALARIAL-DRUGS AGAINST PLASMODIUM-FALCIPARUM IN-VITRO
    CANFIELD, CJ
    PUDNEY, M
    GUTTERIDGE, WE
    EXPERIMENTAL PARASITOLOGY, 1995, 80 (03) : 373 - 381
  • [26] Artemether-Lumefantrine Compared to Atovaquone-Proguanil as a Treatment for Uncomplicated Plasmodium falciparum Malaria in Travelers
    Grynberg, Shiny
    Lachish, Tamar
    Kopel, Eran
    Meltzer, Eyal
    Schwartz, Eli
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2015, 92 (01): : 13 - 17
  • [27] In vitro sensitivity of Plasmodium falciparum to lumefantrine in north-western Thailand
    Pilz, JB
    Wernsdorfer, G
    Sirichaisinthop, J
    Rojanawatsirivet, C
    Wiedermann, G
    Wernsdorfer, WH
    WIENER KLINISCHE WOCHENSCHRIFT, 2004, 116 : 41 - 46
  • [28] In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether
    Tanariya, P
    Tippawangkoso, P
    Karbwang, J
    Na-Bangchang, K
    Wernsdorfer, WH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (05) : 437 - 444
  • [29] EFFICACY OF CHLOROQUINE OR ARTEMETHER-LUMEFANTRINE AGAINST PLASMODIUM VIVAX AND ARTEMETHER-LUMEFANTRINE AGAINST UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN CENTRAL ETHIOPIA
    Hailegiorgis, Bereket
    Hwang, Jimee
    Melaku, Zenebe
    Girma, Samuel
    Teshi, Takele
    Gebresellasie, Sintayehu
    Demeke, Leykun
    Hoos, David
    Gobena, Kedir
    Kassa, Moges
    Jima, Daddi
    Reithinger, Richard
    Malone, Joseph
    Kachur, S. Patrick
    Filler, Scott
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (05): : 374 - 375
  • [30] In Vitro Activity of Pyronaridine against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax
    Price, R. N.
    Marfurt, J.
    Chalfein, F.
    Kenangalem, E.
    Piera, K. A.
    Tjitra, E.
    Anstey, N. M.
    Russell, B.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (12) : 5146 - 5150